Table 8.

Major AEs (> grade 3) associated with available TKIs approved for the use in TC.

	Vandetanib	Cabozantinib	Sorafenib	Lenvatinib	Selpercatinib	Vandetanib
Hepatic impairment ALT ASP					11% 9%
Diarrhea	11%	15.9%	2%	8%	6%
Hypertension	9%	8.4%	4%	41.8%	21%	17%
ECG QT prolonged	8%
Proteinuria		0.9%		10%
Hand foot syndrome		12.6%	6%	3.4%
Fatigue	13%	9.3%	5%	9.2%
Other AEs	Decreased appetite: 4% Rash: 8% Asthenia: 3%	Mucosal inflammation: 2.8% Hypocalcemia: 2.8%		Thromboembolic effects: 3.8%		Neutropenia: 13% Lymphopenia: 17% Anemia: 10%
Discontinuous therapy		n=35/214 16%		n=37 (14.2%)	n=12/531 (2%)	n=5/142 (4%)
Death				n=6		n=1
Reference	(47)	(49)	(43)	(45)	(53)	(54)